TABLE 1.
Characteristics of the patients with multiple myeloma included in the study
| Characteristics | Number of patients |
|---|---|
| Age at time of HCT (%) | |
| <65 | 85 (72%) |
| >65 | 33 (28%) |
| Gender (%) | |
| Female | 51 (43) |
| Male | 67 (56) |
| Race (%) | |
| White | 89 (75) |
| Black | 27 (23) |
| Other | 2(2) |
| HCT (%) | |
| Single | 104 (88) |
| Tandem | 9 (8) |
| Salvage | 5 (4) |
| Number of therapies prior to HCT (%) | |
| 1 | 65 (55) |
| ≥2 | 53 (45) |
| ECOG (%) | |
| 0 | 45 (38) |
| 1 | 65 (55) |
| 2 | 8 (7) |
| Isotype (%) | |
| IgG | 75 (63) |
| IgA | 26 (22) |
| Light chain disease | 17 (14) |
| Serum albumin (gr/d) (median) | 3.5 |
| Beta-2 microglobulin (mg/L) (median) | 3.1 |
| Disease stage (%) | |
| I | 44 (37) |
| II | 30 (25) |
| III | 44 (37) |
| Cytogenetics (%) | |
| High risk | 17 (14) |
| Non-high risk | 83 (70) |
| Not evaluable | 18 (15) |
| Median time from diagnosis to first HCT, months (range) | 10 (4-39) |
| Disease status before HCT (%) | |
| CR or sCR | 25 (21) |
| PR or better | 90 (76) |
| SD | 3 (2) |
| PD | 0 (0.0) |
| Median number of CD34+ cells/kg infused at first HCT (range) | 5.42 (2.06-26.82) |
Note: t (4, 14), t (14, 16) and 17 p was counted as high risk.
Abbreviations: CR, complete response; ECOG, eastern coaporative oncology group performance status; HCT, haematopoietic cell transplant; PD, progressive disease; PR, partial response; sCR, stringent complete response; SD, stable disease.